Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Investigated for use/treatment in depression, irritable bowel syndrome (IBS), and obesity.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.